Ruiz-Leon, BNavas, ASerrano, PEspinazo, MLabrador-Horrillo, MMonsalve, R IJurado, AMoreno-Aguilar, C2023-02-082023-02-082020-02-25Ruiz-León B, Navas A, Serrano P, Espinazo M, Labrador-Horrillo M, Monsalve RI, et al. Successful Adaptation of Bee Venom Immunotherapy in a Patient Monosensitized to Api m 10. J Investig Allergol Clin Immunol. 2020;30(4):296-2981018-9068http://hdl.handle.net/10668/15163Bee venom immunotherapy (BVIT), although highly effective, does not protect 10%-15% of patients allergic to bee stings [1]. Even though the production of allergenic extracts is standardized, the real content of major components is not completely known, given the total content of allergenic proteins and the enzymatic activity of phospholipase A2 (Api m 1) and hyaluronidase (Api m 2). To date, 12 allergens have been described as components of Apis mellifera venom (AMV). Api m 1, Api m 2, Api m 3, Api m 5, and Api m 10 are considered major allergens, and their specific IgE (sIgE) can be determined using commercially available techniques [1].enApi m 10Bee venom allergyEffectiveness of venom immunotherapyMolecular diagnosisAllergensBasophil Degranulation TestBee VenomsBeekeepingDesensitization, ImmunologicHumansHypersensitivityImmune ToleranceImmunizationImmunoglobulin EInsect Bites and StingsMaleMiddle AgedOccupational Exposureresearch article32101173open accessAlérgenosApiculturaDesensibilización inmunológicaExposición profesionalHipersensibilidadInmunizaciónInmunoglobulina EMordeduras y picaduras de insectos10.18176/jiaci.0498http://www.jiaci.org/revistas/doi10.18176_jiaci.0498-suppl-figure_1.pdf